Charlotte-based Alveolus, a leader in the development of non-vascular stenting technologies, announced the closing of a $15 million Series C financing. This significant investment complemented a very successful Series B round of funding for the Company. The capital raised will be used to catalyze the development of the remaining Alveolus product portfolio. The financing was led by Ridgeback Capital Management, LLC, joined by MDS Capital and others from the previous series A and B rounds of financing. Alveolus presented at the SEBIO Investor Forum 2005. For further information, visit http://www.alveolus.com.